Search results
Exelixis Inc (EXEL) Reports Q3 2023 Earnings: Total Revenues of $471.9 Million
GuruFocus.com via Yahoo Finance· 8 months agoExelixis Inc (NASDAQ:EXEL) reported total revenues of $471.9 million for Q3 2023, compared to $411.7...
Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx
Zacks via Yahoo Finance· 5 months agoExelixis, Inc. EXEL announced that it has successfully defended an EU patent for Cabometyx...
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
Zacks via Yahoo Finance· 2 months agoExelixis, Inc. EXEL reported lower-than-expected results for the first quarter. Its shares fell 7%...
Exelixis, Inc.'s (NASDAQ:EXEL) market cap decline of US$208m may not have as much of an impact on...
Simply Wall St. via Yahoo Finance· 1 year agoKey Insights Significantly high institutional ownership implies Exelixis' stock price is sensitive...
Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the...
Simply Wall St. via Yahoo Finance· 2 months agoKey Insights Significantly high institutional ownership implies Exelixis' stock price is sensitive...
Insider Sale: Director Jack Wyszomierski Sells Shares of Exelixis Inc (EXEL)
GuruFocus.com via Yahoo Finance· 3 weeks agoOn June 4, 2024, Jack Wyszomierski, Director at Exelixis Inc (NASDAQ:EXEL), executed a sale of 8,287...
Exelixis, Inc. (NASDAQ:EXEL) Shares Could Be 49% Below Their Intrinsic Value Estimate
Simply Wall St. via Yahoo Finance· 1 year agoKey Insights Exelixis' estimated fair value is US$37.88 based on 2 Stage Free Cash Flow to Equity...
Exelixis, Inc. (NASDAQ:EXEL) Q2 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 11 months agoExelixis, Inc. (NASDAQ:EXEL) Q2 2023 Earnings Call Transcript August 1, 2023 Exelixis, Inc. beats...
Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth
Zacks via Yahoo Finance· 2 years agoExelixis, Inc. EXEL reported earnings of 22 cents in the second quarter of 2022, beating the Zacks...
Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress
Zacks via Yahoo Finance· 7 months agoExelixis (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Efforts to develop...